Which TCA blocks dopamine receptors?

Amoxapine is the tricyclic antidepressant (TCA) recognized for its unique pharmacological profile, which includes the blockade of dopamine receptors. This action differentiates it from other TCAs, as most primarily target norepinephrine and serotonin reuptake. The ability to block dopamine receptors allows amoxapine to potentially address symptoms associated with certain mood disorders, including psychotic features, which may not be adequately managed by traditional antidepressants that do not have dopaminergic activity.

In contrast, other TCAs like Pamelor (nortriptyline), Norpramin (desipramine), and Tofranil (imipramine) focus primarily on the reuptake inhibition of norepinephrine and serotonin, without specifically targeting dopamine receptors. This indicates that amoxapine's additional receptor activity provides a unique therapeutic avenue, particularly for patients with complex depressive symptoms that may benefit from dopaminergic modulation.